Skip to main content
. Author manuscript; available in PMC: 2014 Aug 17.
Published in final edited form as: Clin Cancer Res. 2009 Apr 21;15(9):3189–3195. doi: 10.1158/1078-0432.CCR-08-2999

Table 5.

Mean ± SD Pharmacokinetic Parameters for Plasma 5-FU*

5-FU Maintenance Dose (mg/m2) Vorinostat Dose (mg) Css (ηg/mL) Cmax (ηg/mL) AUC (ηg* hr/mL)
2400 100 0.287 ± 0.044 5.03 ± 4.39 15.3 ± 5.7
2400 200 0.274 ± 0.045 13.1 ± 7.96 24 ± 9.11
2400 300 0.396 ± 0.159 24.5 ± 14.5 68.7 ± 88.1
2400 400 0.432 ± 0.077 26.8 ± 11.4 46.7 ± 10.6
*

ANOVA analysis was performed and only Cmax was statistically significant among the vorinostat treatment groups.